Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

Lung Cancer

Volumn 88, Issue 1, 2015, Pages 24-33

  Kim, Moon Young ^a   Koh, Jaemoon ^a,b   Kim, Sehui ^a,b   Go, Heounjeong ^c   Jeon, Yoon Kyung ^a,b   Chung, Doo Hyun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

CD274; Immunotherapy; MET; Programmed cell death 1; Programmed cell death 1 ligand 2; Squamous cell carcinoma of the lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SCATTER FACTOR RECEPTOR; CD274 PROTEIN, HUMAN; MET PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE DOSAGE; GENE MUTATION; GENETIC TRAIT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; AGED; COMPARATIVE STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84924577386     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.016     Document Type: Article

References (39)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013, 63:11-30.
2. Ginsberg M.S., Grewal R.K., Heelan R.T. Lung cancer. Radiol Clin North Am 2007, 45:21-43.
3. Kenfield S.A., Wei E.K., Stampfer M.J., Rosner B.A., Colditz G.A. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008, 17:198-204.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
6. Reck M., Heigener D.F., Mok T., Soria J.C., Rabe K.F. Management of non-small-cell lung cancer: recent developments. Lancet 2013, 382:709-719.
7. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31:1097-1104.
8. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2:62ra93.
9. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18:2443-2451.
10. Brahmer J.R. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013, 31:1021-1028.
11. Zielinski C., Knapp S., Mascaux C., Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013, 24:1170-1179.
12. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
13. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
14. Iwai Y., Terawaki S., Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005, 17:133-144.
15. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
16. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
17. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10:5094-5100.
18. Mu C.Y., Huang J.A., Chen Y., Chen C., Zhang X.G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011, 28:682-688.
19. Boland J.M., Kwon E.D., Harrington S.M., Wampfler J.A., Tang H., Yang P., et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013, 14:157-163.
20. Taube J.M., Klein A.P., Brahmer J.R., Xu H., Pan X., Kim J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
21. Velcheti V., Schalper K.A., Carvajal D.E., Anagnostou V.K., Syrigos K.N., Sznol M., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 2014, 94:107-116.
22. Liang Z., Zhang J., Zeng X., Gao J., Wu S., Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010, 10:376.
23. Tsuta K., Kozu Y., Mimae T., Yoshida A., Kohno T., Sekine I., et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012, 7:331-339.
24. Koeppen H., Yu W., Zha J., Pandita A., Penuel E., Rangell L., et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: met expression levels are predictive of patient benefit. Clin Cancer Res 2014, 20:4488-4498.
25. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
26. Schildhaus H.U., Heukamp L.C., Merkelbach-Bruse S., Riesner K., Schmitz K., Binot E., et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012, 25:1473-1480.
27. Kim Y.T., Seong Y.W., Jung Y.J., Jeon Y.K., Park I.K., Kang C.H., et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013, 8:171-178.
28. Dearden S., Stevens J., Wu Y.L., Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013, 24:2371-2376.
29. Jeon Y.K., Sung S.W., Chung J.H., Park W.S., Seo J.W., Kim C.W., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54:387-398.
30. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013, 3:1355-1363.
31. Sanmamed M.F., Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 2014, 20:256-261.
32. Chen J., Feng Y., Lu L., Wang H., Dai L., Li Y., et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012, 217:385-393.
33. Xu C., Fillmore C.M., Koyama S., Wu H., Zhao Y., Chen Z., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25:590-604.
34. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-88.
35. Song M., Chen D., Lu B., Wang C., Zhang J., Huang L., et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLOS ONE 2013, 8:e65821.
36. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
37. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6:637-645.
38. Soria J.C., Cruz C., Bahleda R., Delord J.P., Horn L., Herbst R.S., et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013, 49:S798.
39. Badoual C., Hans S., Merillon N., Van Ryswick C., Ravel P., Benhamouda N., et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013, 73:128-138.